Direct-gradient high-performance liquid chromatographic analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans: effect of probenecid.
A gradient high-performance liquid chromatographic analysis for the direct measurement of flumequine, with its acyl glucuronide, in plasma and urine of humans has been developed. In order to prevent hydrolysis and isomerization of flumequine acyl glucuronide, the samples were acidified by the oral intake of four 1.2-g amounts of ammonium chloride per day. In contrast to the acyl glucuronides of non-steroidal anti-inflammatory drugs, flumequine and its acyl glucuronide were stable in urine of pH 5.0-8.0. Flumequine acyl glucuronide is unstable at pH 1.5. In acidic urine (pH 5-6), almost no flumequine is excreted unchanged (1%): it is excreted chiefly as acyl glucuronide (84.2%). Probenecid co-medication reduces the renal excretion rate of flumequine acyl glucuronide from 662 to 447 micrograms/min (p = 0.00080), but not the percentage of glucuronidation.
Vree
T B
TB
Department of Clinical Pharmacy, Sint Radboud Hospital, University of Nijmegen, Netherlands.
van Ewijk-Beneken Kolmer
E W
EW
Nouws
J F
JF
D000890:Anti-Infective Agents / Q000032:analysis* / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D024841:Fluoroquinolones; D005965:Glucuronates / Q000032:analysis* / Q000493:pharmacokinetics* / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011339:Probenecid / Q000494:pharmacology*; D011807:Quinolizines / Q000032:analysis* / Q000493:pharmacokinetics* / Q000652:urine
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D005965:Glucuronates; D011807:Quinolizines; D011339:Probenecid; C012976:flumequine